Pacylex Announces Full Slate of Fall Presentations

Pacylex will present at two upcoming investment conferences and the American Society of Hematology (ASH) Meeting

October 7, 2019

Pacylex is pleased to announce that it has been selected to present at two upcoming investment conferences this fall. The first is the BIO Investor Forum, held on October 22 - 23, 2019 in San Francisco, California. It is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings. Pacylex CEO Michael Weickert is scheduled to present and is scheduling meetings to discuss the company and its lead asset, PCLX-001.

BIO Investor Forum Presentation Details: Tuesday, October 22nd 3:15 PM Elizabethan A.

The second conference is the New York Oncology Investor Conference 2019, held November 12 and 13 in New York City. The National Foundation for Cancer Research is one of the key sponsors. This conference includes leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies and cancer foundations. The presentation schedule has yet to be announced.

Pacylex also had an abstract accepted for presentation as a poster at the 61st ASH Annual Meeting & Exposition, held December 7-10, 2019 in Orlando, Florida. The American Society of Hematology Annual Meeting is the premier event in malignant and non-malignant hematology. The Society's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

The Pacylex poster will be presented on December 8, and the abstract will also be published online in the November supplemental issue of Blood.

ASH Poster Session Details:

Poster Number: 3362

TITLE: Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster II

Date: Sunday, December 8, 2019

Presentation Time: 6:00 PM - 8:00 PM

Location: Orange County Convention Center, Hall B

June 8, 2020